Innovative synthesis enhances safety and scalability of tetrazine amino acids for various bioconjugation applications.
The tetrazine–cyclooctene ligation is among the fastest bioorthogonal reactions known, enabling rapid and selective bioconjugation. Site-specific incorporation of tetrazine-bearing noncanonical amino acids (Tet-ncAAs) into proteins via genetic code expansion has expanded the toolkit for applications in chemical biology, therapeutic conjugation, and live-cell imaging. However, existing synthetic routes to Tet-ncAAs rely on small-scale batch reactions that rely on hazardous reagents and are poorly suited for scale-up. Here, we report both hybrid batch-flow and continuous-flow synthetic approaches for Tet-ncAAs that improve process safety, scalability, and reproducibility. The use of aqueous hydrazine in place of anhydrous hydrazine, 3-mercaptopropionic acid as an organic catalyst in place of metal salts, and a compatible solvent system enables the synthesis under safer, milder, and environmentally friendly conditions. Optimization of the temperature for the reaction revealed a two-step process involving rapid hydrazine addition, followed by cyclization at a lower temperature. This modular process supports multigram-scale synthesis of diverse Tet-ncAAs from commercial precursors and integrates a fully continuous oxidation protocol to access the final tetrazine products. The resulting platform offers a safer, scalable, and sustainable route to Tet-ncAAs that supports the growing demand in antibody–drug conjugates, radioimmunoconjugates, antibody-oligonucleotide, and protein–protein conjugates as well as protein labeling and targeted delivery applications.
No takes yet. Share an insight, caveat, or question.
Gangarde et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: